Found 98 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 38422: Phase 3 Multicenter Double-Blind Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
A study to evaluate posoleucel (ALVR105); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus. We would like to rely on WCG as the IRB of record for this study.
A Phase 3 Double-Blind Randomized Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) AG348-C-018
To compare the effect of mitapivat versus placebo on transfusion burden in subjects with alpha- or beta-transfusiondependent thalassemia (TDT) Transfusion reduction response (TRR), defined as a 50% reduction in transfused red blood cell (RBC) units with a reduction of greater that or equal to 2 units of transfused RBCs in …
ABC008-IBM-201: A Phase II/III Randomized Double-blind Placebo-controlled Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
dosing of ABC008 in subjects with inclusion body myositis (IBM).
A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or …
Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Please see section 1 of the full protocol
Please choose between Voice or SMS based delivery of verification code
or